Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Validity of the PSP for PANSS Outcomes in Schizophrenia
NCT07445217Phase 2Completed
- Sponsor
- Calo Psychiatric Center
- Start
- Mar 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Calo Psychiatric Center. Primary endpoint: Gender difference in the effect of paliperidone treatment at 12 weeks. Started Mar 2008; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07445217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445217.